Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market – Industry Trends and Forecast to 2030

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Published Report
  • Jan 2023
  • Country Level
  • 350 ページ
  • テーブル数: 234
  • 図の数: 106

Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2030
Diagram 市場規模(基準年)
USD MILLION
Diagram Market Size (Forecast Year)
USD MILLION
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market, By Cause  (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) – Industry Trends and Forecast to 2030.

Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Analysis and Insights

The growing prevalence of infectious and respiratory diseases like COVID-19 and acute respiratory distress syndrome and the wide focus on vaccine developments and therapeutic and diagnostic products for these conditions have enhanced the market demand. The advancement in technology for easy supply of products and fast manufacturing facilities are also attributing to the growth of the market. The major market players are highly focused on product launches and approvals during this crucial period. In addition, the government and regulatory bodies are supporting market players with product approval due to surging emergence.

欧州、米国、中国、日本の急性呼吸窮迫症候群(ARDS)市場

欧州、米国、中国、日本の急性呼吸窮迫症候群(ARDS)市場

The Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market is supportive and aims to reduce the disease, thereby improving the recovery and performance of individuals. Data Bridge Market Research analyzes that Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market will grow at a CAGR of 9.9% during the forecast period of 2023 to 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020-2015)

Quantitative Units

Revenue in Million, Pricing in USD

Segments Covered

By Cause  (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy and Online Pharmacy)

Country Covered

 U.S., Japan, China, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands and the Rest of Europe

Market Players Covered

Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., and EUROSETS, among others

Market Definition

Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are hospitalized for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the lungs' tiny, elastic air sacs called alveoli. This fluid build-up causes less oxygen to reach the bloodstream. This deprives the organs of getting enough oxygen for their normal function. People with other illness develops ARDS within a few hours to days after the precipitating injury or infection. The risk of death increases with age, and depending on the severity of the illness, patients surviving the syndrome becomes hard. Severe illness or injury causing damage to the membrane sacs of the lungs leads to ARDS. The most common underlying causes for the said diseases include sepsis, inhalation of harmful substances, severe pneumonia, head, chest or another major injury, coronavirus disease 2019 (COVID-19)  and others.

Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of these are discussed in detail below:

Drivers

  • Increasing prevalence and incidence of acute lung injury

Patients with acute lung injuries are being widely reported due to numerous factors like the increasing aging population and the rising number of patients with sepsis and pneumonia. However, most people are diagnosed with lung injuries and acute respiratory distress syndrome only in the late stages. The said disease is a rapidly progressive condition occurring in patients with damaged lungs, causing bodily fluids to leak. The number of acute respiratory distress syndrome cases and lung injuries is increasing due to the emergence of various respiratory illness-causing viruses in recent years, like COVID-19.

Thereby, the incidence and prevalence of acute respiratory distress syndrome keep increasing. The disease has been widely recognized as a major clinical problem worldwide, carrying high morbidity and mortality burden. Hence, increasing prevalence and incident rates of acute lung injuries and accompanied acute respiratory distress syndrome is expected to drive the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market.

  • Wide range of risk factors for Acute Respiratory Distress Syndrome (ARDS)

There is an enormous range of risk factors being reported for acute respiratory distress syndrome. There are environmental and individual risk factors involved with the syndrome. Patients with ARDS suffer from varying degrees of pulmonary artery vasoconstriction that cause the problem of getting enough oxygen into the blood. Thus, they usually need a ventilator to breathe. ARDS causes high mortality and ameliorates this deadly condition. Sepsis syndrome with multiple organ failure is the most common cause of death, while respiratory failure is second. Moreover, the severity of ARDS is associated significantly with the mortality rate among critically ill COVID-19 patients.

ARDS can be induced by multiple causes, including trauma. Risk factors for ARDS after multiple trauma include traumatic brain and chest injury, severity and duration of shock, number of transfused blood products, and infused crystalloids.

欧州、米国、中国、日本の急性呼吸窮迫症候群(ARDS)市場

Opportunity

  •  Increasing awareness regarding acute respiratory distress syndrome (ARDS)

 Since acute respiratory distress syndrome has multiple different causes, it is usually ignored under common causes of death. The requirement of advanced technical treatment and proper awareness of the condition can substantially decline acute respiratory distress syndrome incidence. As timely diagnosis and prevention are crucial to preventing or recovering faster, the public's attention is most important. Current governments and organizations have broadened the scope of lung injury research to include primary prevention of acute respiratory distress syndrome and reduce the morbidity or mortality rate for the syndrome.

The initiatives that started back are still aiding in the prevention of severe lung infections like ARDS and support biotechnology and pharmaceutical companies to innovate their research for new advancements in treatments. Though there is no proper or specific cure for ARDS, few associations are trying to increase awareness of the syndrome and aid patients in receiving timely healing for their lungs.

Such novel initiative programs and supportive care units started by various healthcare and lung care associations are increasing awareness among people regarding the cause and proper disease management on time. Thereby, increasing awareness regarding ARDS through diverse associations enhances the opportunity for future Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market growth.

Restraint/Challenge

  • High cost of devices and treatments

Though acute respiratory distress syndrome is getting a wide range of advanced treatment options, the longer treatment cost is quite difficult for average-income people to afford. The utilization of critical care and intensive care unit services is increasing worldwide, and its expensive cost is a major concern in the current healthcare system. Patients with acute respiratory distress syndrome are commonly required to have long hospitalizations with frequent monetarization and ventilation usage, consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford a long-term stay get discharged in the initial stages of treatment. However, this increases the possibilities and susceptibilities for new complications in infections, which demands additional healthcare resources and treatment.

Post-COVID-19 Impact on Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market

COVID-19 has positively affected the market's growth as there is a rise in the demand for acute respiratory distress syndrome in the region. During the phase of COVID-19, it was indicated that several cases are asymptomatic, while 20% of COVID-19 cases follow a severe course, necessitating hospitalization. Severe cases of COVID-19 disease will ultimately lead to ARDS and pneumonia. This has been proven to be fatal for infected individuals. As ARDS shows the lung defect by damaging the alveoli, which are tiny air sacs in the lungs, the same level of defect has been observed in COVID-19 patients. This leads to a sudden influx of liquid, causing pneumonia. Hence COVID-19 has positively impacted this market.

Recent Developments

  • In May 2021, Medtronic launched the SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio
  • In July 2020, F. Hoffman-La Roche Ltd launched SARS-CoV-2 rapid antibody test. The test was launched in partnership with SD Biosenseor, Inc. This has helped the company to increase its product portfolio

Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Scope

Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is categorized into five segments based on cause, type, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Cause

  • Coronavirus Disease 2019 (COVID-19)
  • Sepsis
  • Inhalation Of Harmful Substances
  • Severe Pneumonia
  • Others

Based on the cause, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others.

Type

  • Diagnosis
  • Treatment

Based on type, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into diagnosis and treatment.

Route of Administration

  • Oral
  • Parenteral
  • Others

Based on route of administration, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral, and others.

End User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

Based on end user, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare and others.

Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

欧州、米国、中国、日本の急性呼吸窮迫症候群(ARDS)市場

Based on distribution channel, the Europe, U.S., China and Japan acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy and online pharmacy.

Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Country Analysis/Insights

Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market is analyzed, and market size insights and trends are provided by the cause, type, route of administration, end user, and distribution channel as referenced above.

The country covered in the Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market are U.S., Japan, China, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands and the Rest of Europe.

U.S. acute respiratory distress syndrome (ARDS) market is expected to grow due to an increase in the prevalence of acute lung injuries as well as a rise in the number of the patient pool of COVID-19 with ARDS. These are the key contributing factors which is expected to boost the growth of the market in the country.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

欧州、米国、中国、日本の急性呼吸窮迫症候群(ARDS)市場

Competitive Landscape and Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis

欧州、米国、中国、日本の急性呼吸窮迫症候群 (ARDS) 市場の競争状況は、競合他社の詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、プレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。上記のデータ ポイントは、欧州、米国、中国、日本の急性呼吸窮迫症候群 (ARDS) 市場への会社の重点にのみ関連しています。

この市場で活動している主要企業としては、Drägerwerk AG & Co. KGaA、Fisher & Paykel Healthcare Limited.、LivaNova PLC、Gilead Sciences, Inc.、Fresenius SE & Co. KGaA、Besmed Health Business Corp.、Armstrong Medical、Smiths Medical、ResMed、ALung Technologies, Inc.、Medtronic、F. Hoffmann-La Roche Ltd、Hamilton Medical、nice Neotech Medical Systems Pvt. Ltd.、Pfizer Inc.、WEINMANN Emergency Medical Technology GmbH + Co. KG、NIPRO、Terumo Medical Corporation、Getinge AB.、EUROSETS などがあります。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CAUSE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 ETIOLOGY BY GEOGRAPHY

4.3.1 ETIOLOGY IN U.S.

4.3.2 ETIOLOGY IN EUROPE

4.3.3 ETIOLOGY IN CHINA

4.3.4 ETIOLOGY IN JAPAN

4.4 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) HEALTHCARE COST PER PATIENT BY GEOGRAPHY

4.5 INSURANCE REIMBURSEMENT

4.5.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)

4.5.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION

4.5.3 ABBOTT CODING GUIDE FOR ECMO

4.5.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS)

4.5.5 CERN HEALTH INSURANCE SCHEME

4.5.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)

4.5.7 AMERICAN HOSPITAL ASSOCIATION

4.5.8 CONCLUSION

4.6 PIPELINE ANALYSIS

5 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS

5.1 REGULATION IN U.S.:

5.2 LABELING OF MODIFIED DEVICES

5.3 REGULATION IN EUROPE:

5.4 REGULATION IN CHINA:

5.5 REGULATION IN JAPAN:

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY

6.1.2 WIDE RANGE OF RISK FACTORS FOR ACUTE RESPIRATORY DISTRESS SYNDROME

6.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS

6.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES

6.1.5 INCREASING ACCIDENT RATES AND TRAUMA-CAUSING ARDS

6.2 RESTRAINTS

6.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS

6.2.2 HIGH COST OF DEVICE AND TREATMENTS

6.2.3 LACK OF SKILLED WORKFORCE

6.3 OPPORTUNITIES

6.3.1 GROWING GERIATRIC POPULATION

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.4 INCREASING AWARENESS REGARDING ACUTE RESPIRATORY DISTRESS SYNDROME(ARDS)

6.4 CHALLENGES

6.4.1 STRINGENT RULES & REGULATIONS

6.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES

7 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE

7.1 OVERVIEW

7.2 CORONAVIRUS DISEASE 2019 (COVID-19)

7.3 SEPSIS

7.4 INHALATION OF HARMFUL SUBSTANCES

7.5 SEVERE PNEUMONIA

7.6 OTHERS

8 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE

8.1 OVERVIEW

8.2 DIAGNOSIS

8.2.1 IMAGING TESTS

8.2.1.1 CHEST X-RAY

8.2.1.2 CT SCAN

8.2.1.3 ULTRASOUND

8.2.1.4 OTHERS

8.2.2 BLOOD TEST

8.2.3 RESPIRATORY RATE

8.2.4 SPO2 TEST

8.2.5 OTHERS

8.3 TREATMENT

8.3.1 MECHANICAL VENTILATION

8.3.1.1 HIGH-FLOW NASAL O2

8.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE

8.3.1.3 CONTINUOUS POSITIVE AIRWAY PRESSURE

8.3.1.4 PRONE POSITIVE VENTILATION

8.3.1.5 OTHERS

8.3.2 CORTICOSTEROIDS

8.3.2.1 METHYLPREDNISOLONE

8.3.2.2 DEXAMETHASONE

8.3.2.3 OTHERS

8.3.3 ANTIVIRAL MEDICATION

8.3.3.1 REMDESIVIR

8.3.3.2 COMBINATION DRUGS

8.3.3.3 OTHERS

8.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)

8.3.5 TOCILIZUMAB

8.3.6 OTHERS

9 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 PARENTERAL

9.2.1 INTRAVENOUS

9.2.2 INTRAMUSCULAR

9.3 ORAL

9.4 OTHERS

10 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 SPECIALTY CLINICS

10.4 HOME HEALTHCARE

10.5 OTHERS

11 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 HOSPITAL PHARMACY

11.4 RETAIL PHARMACY

11.5 ONLINE PHARMACY

12 EUROPE

12.1 GERMANY

12.2 FRANCE

12.3 U.K.

12.4 ITALY

12.5 SPAIN

12.6 TURKEY

12.7 HUNGARY

12.8 NETHERLANDS

12.9 SWITZERLAND

12.1 AUSTRIA

12.11 LITHUANIA

12.12 POLAND

12.13 RUSSIA

12.14 IRELAND

12.15 NORWAY

12.16 REST OF EUROPE

13 EUROPE, US, CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: U.S.

13.2 COMPANY SHARE ANALYSIS: EUROPE

13.3 COMPANY SHARE ANALYSIS: JAPAN

13.4 COMPANY SHARE ANALYSIS: CHINA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 GILEAD SCIENCES INC.

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUS ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENT

15.2 TERUMO CORPORATION

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUS ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPMENT

15.3 GETINGE AB

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUS ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENT

15.4 LIVANOVA PLC

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPMENTS

15.5 MEDTRONIC

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENTS

15.6 ALUNG TECHNOLOGIES, INC

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 ARMSTRONG MEDICAL

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 BESMED HEALTH BUSINESS CORP.

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 DRÄGERWERK AG & CO. KGAA

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 EUROSETS

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 F. HOFFMANN-LA ROCHE LTD

15.11.1 COMPANY SNAPSHOT

15.11.2 RECENT ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENTS

15.12 FISHER & PAYKEL HEALTHCARE LIMITED

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.13 FRESENIUS SE & CO. KGAA

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUS ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 HAMILTON MEDICAL

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 NIPRO

15.16.1 COMPANY SNAPSHOT

15.16.2 REVENUS ANALYSIS

15.16.3 PRODUCT PORTFOLIO

15.16.4 RECENT DEVELOPMENT

15.17 PFIZER INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 REVENUS ANALYSIS

15.17.3 PRODUCT PORTFOLIO

15.17.4 RECENT DEVELOPMENT

15.18 RESMED

15.18.1 COMPANY SNAPSHOT

15.18.2 REVENUE ANALYSIS

15.18.3 PRODUCT PORTFOLIO

15.18.4 RECENT DEVELOPMENT

15.19 SMITHS MEDICAL

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUS ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

15.2 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG

15.20.1 COMPANY SNAPSHOT

15.20.2 PRODUCT PORTFOLIO

15.20.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

表のリスト

TABLE 1 HEALTHCARE COST FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ON THE BASIS OF SEVERITY BY COUNTRY IS GIVEN BELOW IN USD:

TABLE 2 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS

TABLE 3 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA

TABLE 4 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES

TABLE 5 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 6 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 7 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 8 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 10 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 11 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 12 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 13 EUROPE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 14 U.S. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 15 CHINA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 16 JAPAN DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 17 EUROPE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 18 U.S. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 19 CHINA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 20 JAPAN IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 21 EUROPE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030(USD MILLION)

TABLE 22 U.S. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 23 CHINA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 24 JAPAN TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 25 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 26 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 27 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 28 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 29 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 30 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 31 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 32 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 33 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 34 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 35 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 36 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 38 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 39 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 40 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 41 EUROPE PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 42 U.S. PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 43 CHINA PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 44 JAPAN PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 45 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 46 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 48 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 49 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 50 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 51 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 52 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 53 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 54 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 55 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 56 GERMANY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 57 GERMANY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 58 GERMANY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 59 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 60 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 61 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 62 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 63 GERMANY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 64 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 65 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 66 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 67 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 68 FRANCE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 69 FRANCE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 70 FRANCE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 71 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 72 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 73 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 74 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 75 FRANCE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 76 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 77 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 78 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 79 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 80 U.K. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 81 U.K. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 82 U.K. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 83 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 84 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 85 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 86 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 87 U.K. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 88 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 89 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 90 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 91 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 92 ITALY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 93 ITALY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 94 ITALY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 95 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 96 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 97 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 98 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 99 ITALY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 100 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 101 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 102 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 103 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 104 SPAIN DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 105 SPAIN IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 106 SPAIN TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 107 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 108 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 109 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 110 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 111 SPAIN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 112 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 113 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 114 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 115 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 116 TURKEY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 117 TURKEY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 118 TURKEY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 119 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 120 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 121 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 122 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 123 TURKEY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION

TABLE 124 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 125 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 126 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 127 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 128 HUNGARY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 129 HUNGARY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 130 HUNGARY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 131 HUNGARY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 132 HUNGARY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 133 HUNGARY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 134 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 135 HUNGARY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 136 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 137 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 138 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 139 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 140 NETHERLANDS DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 141 NETHERLANDS IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 142 NETHERLANDS TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 143 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 144 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 145 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 146 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 147 NETHERLANDS PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 148 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 149 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 150 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 151 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 152 SWITZERLAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 153 SWITZERLAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 154 SWITZERLAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 155 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 156 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 157 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 158 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 159 SWITZERLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 160 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 161 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 162 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 163 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 164 AUSTRIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 165 AUSTRIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 166 AUSTRIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 167 AUSTRIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 168 AUSTRIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 169 AUSTRIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 170 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 171 AUSTRIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 172 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 173 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 174 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 175 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 176 LITHUANIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 177 LITHUANIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 178 LITHUANIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 179 LITHUANIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 180 LITHUANIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 181 LITHUANIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 182 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 183 LITHUANIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 184 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 185 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 186 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 187 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 188 POLAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 189 POLAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 190 POLAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 191 POLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 192 POLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 193 POLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 194 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 195 POLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 196 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 197 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 198 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 199 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 200 RUSSIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 201 RUSSIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 202 RUSSIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 203 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 204 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 205 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 206 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 207 RUSSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 208 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 209 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 210 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 211 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 212 IRELAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 213 IRELAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 214 IRELAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 215 IRELAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 216 IRELAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 217 IRELAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 218 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 219 IRELAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 220 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 221 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 222 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 223 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 224 NORWAY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 225 NORWAY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 226 NORWAY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 227 NORWAY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 228 NORWAY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 229 NORWAY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 230 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 231 NORWAY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 232 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 233 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 234 REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

図表一覧

FIGURE 1 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 2 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS

FIGURE 4 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: END USER COVERAGE GRID

FIGURE 9 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 11 ACCELERATION IN THE PATIENT POOL OF COVID-19 WITH ARDS IS EXPECTED TO DRIVE THE EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 13 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S.ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 14 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 15 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 16 MOST COMMON PRIMARY CAUSES OF DEATH IN ARDS PATIENTS IN U.S. COUNTRY

FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

FIGURE 18 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 19 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 20 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 21 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 22 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 23 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 24 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 25 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 26 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 27 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 28 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 29 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 30 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 31 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 32 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 33 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 34 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 35 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 36 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 38 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 39 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 40 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 41 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 42 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 43 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 44 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 45 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 46 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 47 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 48 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 49 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 50 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 51 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 52 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 53 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 54 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 55 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 56 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 57 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 58 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 59 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 60 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 61 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 62 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 63 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 64 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 65 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 66 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 67 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 68 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 69 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 70 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 71 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 72 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 73 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 74 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 75 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 76 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 77 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 78 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 79 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 80 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 81 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 82 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 83 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 84 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 85 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 86 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 87 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 88 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 89 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 90 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 91 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 92 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 93 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 94 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 95 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 96 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 97 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 98 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SNAPSHOT (2022)

FIGURE 99 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022)

FIGURE 100 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2023 & 2030)

FIGURE 101 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022 & 2030)

FIGURE 102 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: CAUSE (2023-2030)

FIGURE 103 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

FIGURE 104 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

FIGURE 105 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

FIGURE 106 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market is projected to grow at a CAGR of 9.9% during the forecast period by 2030.
The Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market is segmented on the basis of cause, type, route of administration, end-user, and distribution channel.
The major players in the Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market are Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, etc.
The countries covered in the Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market are U.S., Japan, China, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands and the Rest of Europe.